Anti‐PD‐1 checkpoint blockade treatment and PTT induced by CuS NPs could eradicate primary tumors and suppress their metastasis.[91] Combining immune checkpoint blockade treatment (anti‐PD‐L1) and PTT with maleimide PEG‐modified CuS NPs with tumor antigen adsorption capacity enhanced the serum levels of inflammatory cytokines and the amount of tumor‐infiltrating CD8+ T cells.[92]. This evidence concerns the gene CD8A and neoplasm.